好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Is the Latency from Progressive Supranuclear Palsy Onset to Diagnosis Improving?
Movement Disorders
P3 - Poster Session 3 (5:30 PM-6:30 PM)
10-025

We posed the hypothesis that the latency from PSP symptom onset to diagnosis has improved over the past 3 decades.
Progressive supranuclear palsy (PSP) is a neuropathologically defined disease with a broad clinical spectrum. It can initially be mistaken for other neurodegenerative diseases. Diagnosis of PSP earlier in the course may reduce its psychological and financial burden, permit earlier access to neuroprotective interventions and avoid unnecessary diagnostic and therapeutic measures. Our impression is that physicians are more aware of PSP in the 2010s than in the 1990s. This study tests that hypothesis using the latency from symptom onset to PSP diagnosis as a surrogate outcome.
We reviewed records of 385 patients with “possible” or “probable” PSP from 1990 to 2016 at the Movement Disorders Center, Rutgers Robert Wood Johnson Medical School.  The time from symptom onset to diagnosis was calculated for each patient and labeled as latency. We used Pearson correlation, Student t-test and ANOVA as appropriate.
Our data showed the mean latency (SD) from symptom onset to diagnosis PSP, in months, was 43.76 (25.60) in the 1990s, 40.76 (28.73) in the 2000s and 29.15 (16.80) in the 2010s (p < .001). There was also an inverse relationship between age at onset and latency (Pearson r = -0.23, p < .001).  This had no effect on the statistical significance of our main observation.
Our finding suggest that there is a progressive reduction in the latency over the past 3 decades.  It may reflect increased awareness of PSP by physicians in our referral area.
Authors/Disclosures
Mansoureh Mamarabadi, MD
PRESENTER 		Dr. Mamarabadi has nothing to disclose.
No disclosure on file
Lawrence I. Golbe, MD Dr. Golbe has received personal compensation in the range of $0-$499 for serving as a Consultant for Amylyx. Dr. Golbe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Aprinoia. Dr. Golbe has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ferrer. Dr. Golbe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitochon. Dr. Golbe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for IQVIA. Dr. Golbe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Woolsey. Dr. Golbe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ferrer. Dr. Golbe has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Rossy Centre. Dr. Golbe has received intellectual property interests from a discovery or technology relating to health care. Dr. Golbe has received publishing royalties from a publication relating to health care. Dr. Golbe has a non-compensated relationship as a Chief Clinical Officer, Scientific Advisory Board Chair, Member of the Board of Directors, all as a volunteerd with CurePSP that is relevant to AAN interests or activities.